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Abstract
Introduction: The aim of this study was to examine the effectiveness of innovative peptides obtained by addition of 
polypeptide motifs with antiaggregation activity (Arg-Gly-Asp, Lys-Gly-Asp and Pro-Gly-Pro) to a peptide mimicking 
the tertiary structure of the α-helix B of erythropoietin pHBSP (Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser).
Materials and methods: The cytoprotective activity of innovative peptides mimicking the tertiary structure of the 
α-helix B of erythropoietin at the doses of 5 μg/ml, 30 μg/ml and 50 μg/ml was studied on human endothelial cell cul-
ture in a simulated oxidative stress. An ADMA-like model of preeclampsia was simulated in the experiment. The study 
was conducted in 260 female Wistar rats, weighing 250–300 g.
Results and discussion: Innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin retain 
their cytoprotective activity in a simulated oxidative stress in HUVEC cell culture at the doses of 5 μg/ml, 30 μg/ml, and 
50 μg/ml. The compounds with laboratory codes P-αB1 and P-αB3 had the most pronounced cytoprotective activity. 
Administration of N-nitro-L-arginine-methyl ether to pregnant females for 7 days causes the morphofunctional changes 
similar to clinical changes in preeclampsia. The innovative peptide under laboratory code P-αB4 at the dose of 50 μg/
kg mimicking the tertiary structure of the α-helix B of erythropoietin shows the most pronounced protective properties.
Conclusion: Innovative peptides mimicking the tertiary structure of the α-helix B of erythropoietin have a pronounced 
positive influence on the morphofunctional disorders in animals with ADMA-like preeclampsia.
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Introduction
Preeclampsia is a complex multi-factorial disease and is 
traditionally characterized by a combined manifestation 
of edema, hypertension, and proteinuria. According to 
various authors, it affects from 2% to 10% of all pregnan-
cies (Un Nisa et al. 2019; Messerli et al. 2019; Tomimatsu 
et al. 2019). In 0.03–0.055%, it develops into eclampsia 
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(Olaoye et al. 2019). After bleeding, it is the next leading 
cause in the structure of maternal and child morbidi-
ty and mortality in developed and developing countries 
(Ponmozhi et al. 2019, Lee et al. 2019), and especially in 
low-income countries (Olaoye et al. 2019). In the Russian 
Federation, arterial hypertension complicates 5–30% of 
the total number of pregnancies. The incidence of arterial 
hypertension, edema and proteinuria during pregnancy in 
the Russian Federation is approximately 17% of the total 
number of pregnancies; preeclampsia and eclampsia are 
diagnosed in about 2% of all pregnancies.
Despite a large number of studies on the prevention 
and treatment of preeclampsia, the results of a drug treat-
ment are still unsatisfactory. Currently, delivery is the 
only radical treatment for preeclampsia. Other methods 
of treatment are aimed at the correction the mother’s con-
dition, which in turn contributes to improvement of the 
fetal condition. They include prevention of the convulsive 
syndrome, hypotensive therapy, correction of disorders of 
the electrolyte balance and hemostasis system. Other are-
as of the therapy are not yet yielding the expected result.
Many authors consider placental ischemia, endotheli-
al dysfunction, and platelet aggregation disorders as the 
main pathogenetic links in the pathogenesis of preec-
lampsia (Granger et al. 2018; Jakobsen et al. 2019; Sea-
mon et al. 2020).
Based on the main features of preeclampsia, one of the 
promising directions for creating new drugs for the treat-
ment and prevention of preeclampsia is the use of drugs 
with anti-ischemic and cytoprotective activities. Such a 
pharmacological agent is 11-amino acid peptide pHB-
SP (PubChem CID: 91810664), which is an amino acid 
chain QEQLERALNSS (Pyr-Glu-Gln-Leu-Glu-Arg-Ala-
Leu-Asn-Ser-Ser), having a selective affinity for the het-
erodimer complex EPOR/CD131 (Hache et al. 2016). The 
short peptide chain allows its modification by adding the 
polypeptide motifs RGD (Arg-Gly-Asp), KGD (Lys-Gly-
Asp) and PGP (Pro-Gly-Pro), which are known for their 
anti-aggregation properties (Pastorova et al. 2001; Lyapi-
na et al. 2007; Liapina et al. 2010; Obergan et al. 2019; 
Kuo et al. 2019). The key issue remains the retention of 
protective properties of innovative peptides mimicking 
the tertiary structure of the α-helix B of erythropoietin af-
ter embedding RGD, KGD and PGP motifs into the base 
molecule. The presented provisions determined the aim 
of the research.
Aim of the study: to study innovative peptides that 
mimic the tertiary structure of the α-helix B of erythropoi-
etin in experimental preeclampsia.
Materials and methods
Study of cytoprotective activity
A modification of the method described by Eric A. Jaffe 
was used to obtain primary cultures of endotheliocytes 
from the human umbilical cord vein. The vein cavity was 
first aseptically washed with DPBS (Thermo FS) until 
blood was completely removed, then filled with 0.2% col-
lagenase solution in DPBS with the addition of 0.9 mM 
CaCl2, 0.493 mM MgCl2, 5.56 mM glucose, 0.327 mM 
sodium pyruvate, and subjected to enzymatic dissociati-
on of the inner layer of the vein – intima. To do this, the 
umbilical cord was transferred to a glass with DPBS and 
incubated at 37oC for 20 minutes. A collagenase solution 
containing cells was collected in a 50 ml tube by perfu-
sion of the vein cavity with 20 ml of medium 199 (Sig-
ma-Aldrich). The obtained endothelial cells were cultured 
in DMEM medium with the addition of 20 mM of HEPES 
buffer, 5 U/ml of heparin, 200 mcg/ml of E CG F (Sig-
ma-Aldrich), 10% embryonic veal serum (FBS) at 37 °C 
in a humid atmosphere containing 5% CO2.
The cells were cultured in 96-well plates covered with 
gelatin, with a density of 5 thousand cells per well. After 
24 hours of incubation, the studied peptides (P - αB, P - αB 
1, P - αB 2, P - αB 3, P - αB 4, P - αB 5, P - αB 6) were 
introduced in 3 concentrations – 5 mcg/ml, 30 mcg/ml, and 
50 mcg/ml. Three hours after peptides introduction, hydro-
gen peroxide (H2O2) was added to the wells of the plate at a 
final concentration of 200 mcM. After 24 hours, the culture 
medium containing H2O2 was replaced with a normal one.
Cell viability was measured using an MTT test. The 
principle of the method is based on the ability of succi-
nate dehydrogenase, an enzyme of the mitochondrial 
membrane, to reduce the yellow salt 3-[4,5-dimethylth-
iazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) to 
purple formazan crystals that accumulate as a result of 
this reaction in the cytoplasm of living cells. Thus, the 
level of mitochondrial respiration of the cell was judged 
by the intensity of accumulation of formazan crystals in 
the cytoplasm, which is an indicator of its viability. The 
amount of formazan formed in the cell monolayer is pro-
portionally correlated with the number of living cells in 
the test sample.
At the end of the experiment, the medium was sampled, 
and the solution of 3-(4,5-dimethylthiazole-2-yl)-2,5-di-
phenyl-tetrazolium bromide (MTT, Sigma) in PBS (Sig-
ma), containing 0.9 mM CaCl2 and 0.5 mM MgCl2, was 
added to the wells of the plate at the rate of 10 mg MTT 
per well. After a 4-hour incubation at 37 °C in a humid at-
mosphere with 5% CO2, the plate was centrifuged at 600g 
using a centrifuge R4810 (Eppendorf, Germany). The su-
pernatant was carefully aspirated.
DMSO, 250 µl/well, was used to dissolve the formed 
formazan crystals. After complete dissolution of the crys-
tals, 150 µl, without affecting the cell layer on the gela-
tin, was transferred to a new plate. The optical density of 
the formazan solution in DMSO was measured using a 
spectrophotometer Multiscan EX at a wavelength of 570 
nm. By changing the optical density, the cytoprotective 
activity of peptides was judged. The MTT test results 
were evaluated by comparing the optical density in the 
experimental and control wells. Survival in each group 
was evaluated in relation to intact cells as the ratio of op-
tical densities (Zal et al. 2018).
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In vivo experiments
The experimental study was performed in The Research 
Institute of Pharmacology of Living Systems of Belgorod 
State National Research University (BelSU). The study 
was performed in accordance with the requirements of 
GOST ISO/IEC 17025-2009, GOST R ISO 5725-2002 
and “Good Laboratory Practices”, approved by order No. 
199n of the Ministry of Health of the Russian Federati-
on dated 1 April 2016, in compliance with The European 
Convention for the Protection of Vertebral Animals Used 
for Experimental and Other Scientific Purposes (Direc-
tive 2010/63/EU). All the experiments were approved by 
the Bioethical Commission of The Research Institute of 
Pharmacology of Living Systems of BelSU. Vivisection 
was performed in accordance with the ethical principles 
of handling laboratory animals – The European Conven-
tion for the Protection of Vertebral Animals Used for Ex-
perimental and Other Scientific Purposes. CETS No. 170.
The experimental animals were held in individually 
ventilated cages Tecniplast for small laboratory animals. 
The flooring was sawdust sterilized by UV irradiation. 
Feed was granulated for small laboratory animals – ro-
dents. Water was purified and sterilized by UV irradiation. 
The microclimate was created and maintained by a sys-
tem of individually ventilated cages. Acclimatization and 
selection of animals for research were carried out after 
a quarantine for at least 10 days. Distribution by groups 
was according to animals’ body weight. Identification of 
the animals was performed by writing an individual label 
on the body.
At the time of the study, the animals were healthy, with 
no changes in behavior, appetite, or sleep-wake schedule. 
For 18 hours before the experiments, the animals were 
completely deprived of food, with free access to water.
The study was performed in 260 white female Wistar 
rats, weighing 250–300 g. The animals with specific ges-
tation periods were obtained by introducing males to fe-
males in a ratio of 2:3. Twenty-four hours later, the ani-
mals were separated, and on the 10th day, under sedation, 
pregnancy was determined by palpation. Simulation of 
ADMA-like preeclampsia was performed by intraperi-
toneal administration of a non-selective NOS blocker 
N-nitro-L-arginine-methyl ether (L-NAME) (25 mg/kg/
day) from the 14th to the 20th day of pregnancy. On the 
21st day, under anesthesia (chloral hydrate 300 mg/kg), 
hemodynamic parameters were registered, and endothe-
lial function was studied using a Biopac (USA) hard-
ware complex (Gureev et al. 2014; Gureev et al. 2015; 
Korokin et al. 2015).
The concentration of stable metabolites of nitric ox-
ide (total NOx) was a biochemical marker of endothe-
lial dysfunction. The level of NO metabolites (i.e. the 
total concentration of nitrates and nitrites, NOx) was 
determined by a colorimetric method based on the de-
velopment of color in the diazotization reaction with 
sulfanilamide nitrite, which is part of the Griss reagent 
(Metel’skaia et al. 2005).
To obtain the data on the state of microcirculation in 
the placenta on the 21st day of pregnancy, the level of mi-
crocirculation was measured under anesthesia, at 4 points 
at a distance of 1 mm from the edge of the placental disk. 
To obtain the data on the state of microcirculation in the 
placenta, we used the equipment manufactured by Biopac 
systems: a MP100 polygraph with a LDF100C laser Dop-
pler flowmetry module and a TSD144 invasive needle 
sensor, which was placed directly on the projection of the 
placental disc. Registration and processing of LDF results 
was performed using the AcqKnowledge program version 
3.8.1.; the values of microcirculation were expressed in 
perfusion units (PU) (Gureev et al. 2015; Severinova et 
al. 2019; Korokin et al. 2020).
Urine collection was performed for 12 hours, using 
special metabolic cages. Determination of the amount 
of protein in daily urine was performed by the pyrogall 
method, using a PE-5400B spectrophotometer (Yalamati 
et al. 2015).
To study the liquid content in the greater omentum, it 
was weighed and then dried at 37 °C for 24 hours and re-
weighed (Ivanova et al. 2012; Gureev et al. 2015).
To conduct a morphometrical study, the material was 
fixed in 10% formalin with subsequent embedding in par-
affin. Slices of the kidneys were made perpendicular to 
the main axis of the organ through the pelvis. Histologi-
cal slices of the placenta were made in a strictly vertical 
direction through the middle of the placental disk, all the 
layers of the placenta and the wall of the uterine horn. The 
study of microsections, photo protocoling and morphom-
etry was performed using a Leica DM4000B microscope, 
with a video recording and image processing system. 
In all the morphological studies, hematoxylin and eosin 
staining was used.
To assess the growth and weight indicators, the fetus-
es were extracted from the uterine cavity, weighed, and 
their growth was measured (craniocaudal size), followed 
by the calculation of the growth and weight coefficient 
(Mironov et al. 2012).
According to the aim, all the animals were divided into 
the following groups:
1. Intact group (animals with oral administration of 
NaCl in equivalent doses from the 14th to the 20th day 
of pregnancy).
2. Simulation of experimental preeclampsia (control) 
(L-NAME (25 mg/kg once per day intraperitoneally) 
from the 14th to the 20th day of pregnancy).
3. Simulation of experimental preeclampsia + meth-
yldopa (2 × 0.043 g/kg/day intragastrically).
4. Simulation of experimental preeclampsia + P-αB 
(50 μg/kg).
5. Simulation of experimental preeclampsia + P-αB1 
(50 μg/kg).
6. Simulation of experimental preeclampsia + P-αB2 
(50 μg/kg).
7. Simulation of experimental preeclampsia + P-αB3 
(50 μg/kg).
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8. Simulation of experimental preeclampsia + P-αB4 
(50 μg/kg).
9. Simulation of experimental preeclampsia + P-αB5 
(50 μg/kg).
10. Simulation of experimental preeclampsia + P-αB6 
(50 μg/kg).
11. Simulation of experimental preeclampsia + P-αB4 
(10 μg/kg).
12. Simulation of experimental preeclampsia + P-αB4 
(10 μg/kg) + methyldopa (2 × 0.043 g/kg/day intra-
gastrically).
13. Simulation of experimental preeclampsia + P-αB4 
(50 μg/kg) + methyldopa (2 × 0.043 g/kg/day intra-
gastrically).
Statistical processing of research results
Statistical processing was performed using the compu-
ting software environment R. The pattern of feature dis-
tribution in the statistical sample was determined using 
the Shapiro-Wilk test and the Spiegelhalter test (norm-
test library), and the equality of variances was estimated 
using the Levene’s test (lawstat library). Depending on 
the type of feature distribution and equality of variances, 
the significance of the results was evaluated, using pa-
rametric (ANOVA) or non-parametric (Kruskal-Wallis 
test) one-way analysis of variance, and as a post-hoc ana-
lysis to identify differences in intergroup comparisons, 
the Student’s unpaired t-test or the Mann-Whitney test, 
respectively, with the Benjamini-Hochberg correction for 
multiple hypothesis testing. The results were considered 
significant at p ≤ 0.05.
Results and discussion
Study of cytoprotective activity of peptides mimicking 
the tertiary structure of the α-helix B of erythropoietin
Introduction of the studied innovative peptides to the 
HUVEC cell culture, against the background of oxidative 
stress, resulted in a statistically significant increase in op-
tical density. This indicates an increase in mitochondrial 
activity and cell survival in the cell culture. The increase 
in the level of cytoprotective activity with an increase in 
the concentration of innovative peptides was not statis-
tically significant, and the compounds with laboratory 
codes PaB1 and PaB3 had the most pronounced cytopro-
tective activity (Fig. 1).
Study of the effect of peptides mimicking the α-helix B 
of erythropoietin on the development of morphofunc-
tional disorders in ADMA-like preeclampsia
After L-NAME administration to pregnant rats, there 
was a significant increase (p < 0.05) in systolic and dias-
tolic blood pressure from 128.8 ± 2.61 mm Hg and 82.2 
± 3.27 mm Hg to 202.8 ± 6.86 mm Hg and 138.40 ± 2.95 
mm Hg, respectively. There was a disruption of the reg-
ulatory mechanisms of vascular tone, as evidenced by 
an increase in the CED from 1.25 ± 0.04 to 3.11 ± 0.20 
(p < 0.05). In the placenta, microcirculation decreased 
from 541 ± 23.4 PU to 218 ± 6.4 PU (p < 0.05). In the 
blood plasma, there was a decrease in the concentration 
of terminal NO metabolites from 2.22 ± 0.04 mmol/DL to 
1.36 ± 0.05 mmol/DL, which indicates a decrease in the 
NO-synthesizing function of the endothelium. Simulated 
ADMA-like preeclampsia caused an increase in proteinu-
ria and swelling of the greater omentum tissues.
Histological examination of the placental microsec-
tions on the 21st day of gestation in the animals with 
ADMA-like preeclampsia revealed changes of ischemic 
genesis. The morphological pattern was accompanied by 
a statistically significant (p < 0.05) decrease in the thick-
ness of the fetal part from 0.950 ± 0.128 microns to 0.645 
± 0.0091 microns and an increase in the thickness of the 
maternal placenta (p < 0.05) from 0.325 ± 0.005 to 0.532 
± 0.009 microns. In addition, there was a decrease in the 
density of the cell pool of both the maternal and fetal parts 
of the placenta and a decrease in the diameter of the villi. 
A study of the fetal development in the animals with AD-
MA-like preeclampsia revealed fetal hypotrophy.
Intraperitoneal administration of the peptide (P-αB) 
mimicking the α-helix B of erythropoietin (50 μg/kg) 
during the period from the 10th to 20th days of pregnan-
cy led to a statistically significant (p < 0.05) decrease in 
systolic and diastolic blood pressure to 142.8 ± 1.98 and 
90.40 ± 5.21 mm Hg, respectively (p < 0.05) compared 
to the group of “untreated” animals (Table 2). The coeffi-
cient of endothelial dysfunction decreased to 2.0 ± 0.06, 
and the microcirculation index increased to 343 ± 6.0 PU 
(p < 0.05).
The most pronounced hypotensive effect after admin-
istration of the innovative peptides mimicking the α-helix 
B of erythropoietin was observed in P-αB4 (Table 2). Sys-
tolic and diastolic blood pressure after its administration 
reached a level not statistically distinguishable from that 
in the group of intact animals. In addition, a marked de-
crease in blood pressure was observed under the influence 
of peptides: P-αB1 and P-αB3, but it did not reach the 
level of the intact animals. The least pronounced effect 
was observed for peptides P-αB2 and P-αB6.
Table 1. Amino acid sequence of the studied peptides.
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Table 2. The effect of innovative peptides mimicking the α-helix B of erythropoietin on functional parameters in ADMA-like Pre-
eclampsia (M ± m, n = 10).
Group Indicator




Proteinuria, g/L NOx, µmol/DL Edema of 
the greater 
omentum, %
Intact 128.8±2.61y 80.8±3.27y 1.25±0.04y 541±23.4y 0.29±0.10y 2.22±0.04y 44.74±1.16y
L-NAME 202.8±6.86* 138.4±2.95* 3.11±0.20* 218±6.4* 2.57±0.11* 1.36±0.05* 54.12±1.31*
P-αB (50 μg/kg) 142.8±1.98*y 90.4±5.21* 2.0±0.06*y 343±6.0*y 1.88±0.18*y 1.59±0.05*y 49.07±1.16*y
P-αB1 (50 μg/kg) 143.1±5.18* 100.6±3.80* 1.80±0.15*y 378±9.45*y 0.58±0.18y 1.83±0.04*y 48.67±0.74*y
P-αB2 (50 μg/kg) 172.8±5.06*y 135.2±3.54*y 2.25±0.16*y 351±10.04*y 1.21±0.21*y 1.60±0.08*y 49.25±0.74*y
P-αB3 (50 μg/kg) 144.8±4.49*y 104.3±3.36*y 1.98±0.19*y 370±9.2*y 0.66±0.16y 1.71±0.07*y 48.14±0.88*y
P-αB4 (50 μg/kg) 138.3±5.44y 94.0±6.59y 1.80±0.22*y 337±8.7*y 0.51±0.14y 1.80±0.06*y 46.33±0.53*y
P-αB5 (50 μg/kg) 168.7±5.68*y 124.5±5.72*y 2.19±0.16*y 322±6.8*y 2.00±0.12*y 1.46±0.04* 49.64±0.70*y
P-αB6 (50 μg/kg) 174.6±6.58*y 129.7±5.75*y 2.67±0.28*y 303±6.4*y 2.46±0.19* 1.50±0.05* 52.40±1.10*y
Note: SBP and DBP – systolic and diastolic blood pressure; CED – coefficient of endothelial dysfunction; PU – perfusion units; NOx – terminal NO 
metabolites; * – p ˂ 0.05 in comparison with the control group; y – p ˂ 0.05 in comparison with the L-NAME group.
Figure 1. Effect of innovative peptides mimicking the α-helix B of erythropoietin on the viability of HUVEC cell culture in the 
simulated oxidative stress. Note: * – p < 0.05 compared to the control group.
When administering the studied innovative peptides 
mimicking the α-helix B of erythropoietin, it was found 
that the greatest endothelial protective effect was ob-
served in P-αB1, P-αB3, and P-αB4 (Table 2). The coeffi-
cient of endothelial dysfunction decreased to 1.80 ± 0.15, 
1.98 ± 0.19, and 1.80 ± 0.22, respectively. Peptides P-αB2 
and P-αB5 also decreased the CED, but much less. In the 
group of animals administered with P-αB6, the CED was 
lower than in the control group of animals, but there was 
no statistically significant difference.
The most pronounced improvement in the placental 
microcirculation occurred after P-αB1 and P-αB3 admin-
istration. Its values rose to 378 ± 9.45 PU and 370 ± 9.2 
PU, respectively, but it did not reach the target level (Ta-
ble 2). Administration of the other studied peptides also 
improved the placental microcirculation, but the effects 
were significantly less pronounced.
The study of the NO-synthesizing function of the en-
dothelium was carried out on the basis of the determi-
nation of NOx nitrite ions in blood plasma. Simulated 
ADMA-like preeclampsia led to a decrease in the content 
of terminal NOx metabolites in blood plasma (Table 2). 
Intraperitoneal administration of the peptide (P-αB) mim-
icking the α-helix of B erythropoietin (50 μg/kg) from the 
10th to 20th days of pregnancy resulted in a statistically 
significant (p < 0.05) increase in terminal NOx metabo-
lites compared to the group of the “untreated” animals.
After the administration of the studied innovative pep-
tides mimicking the α-helix B of erythropoietin at the 
dose of 50 μg/kg, the greatest increase in the concentra-
tion of nitrite ions (NOx) in blood plasma in the animals 
with ADMA-like preeclampsia (p < 0.05) occurred under 
the influence of P-αB1, P-αB3, and P-αB4 and amounted 
to 1.83 ± 0.04 mmol/DL, 1.71±0.07 mmol/DL and 1.80 ± 
0.06 mmol/DL, respectively, but the target level (groups 
of intact animals (2.22 ± 0.04 mmol/DL)) were not 
achieved. When P-αB2 was administered, there was also 
an increase in the concentration of NOx terminal metabo-
lites in blood plasma, but this effect was less pronounced.
The administration of the studied innovative peptides 
mimicking the α-helix B of erythropoietin in the animals 
with experimental preeclampsia led to a decrease in pro-
teinuria. The most pronounced effect was observed in the 
groups administered with P-αB1, P-αB3, and P-αB4. The 
level of proteinuria did not differ statistically from that of 
the intact animals. There was no statistically significant 
decline in the group administered with P- αB6 in relation 
to the control group of animals. The values of proteinuria 
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in the groups administered with P-αB2 and P-αB5 were in 
between (Table 2).
The study of the content of fluid in the greater omen-
tum tissues, which is a reflection of the edema severity, 
showed its increase in the group of animals with exper-
imental preeclampsia (Table 2). The most pronounced 
positive effect is observed when administering P-αB4. 
The level of fluid content after its administration reduced 
to the level of no statistically significant difference com-
pared to the group of intact animals. The administration 
of P-αB1, P-αB2, P-αB3 and P-αB5 also decreased the 
swelling of the greater omentum tissues, with a less pro-
nounced effect. There was no statistically significant ef-
fect when P-αB6 was administered.
In the histological study of the placenta, the most 
pronounced positive effect was observed in the group 
of animals administered with P-αB4. This is evidenced 
by the results of morphometry. When correcting the cell 
pool in the maternal and fetal parts of the placenta, the 
most pronounced effect is observed for P-αB4. But the 
target level is not reached. The same pronounced effect 
is observed with the administration of P-αB1, P-αB2, and 
P-αB3. When P-αB5 or P-αB6 is administered, the effect 
is absent or minimal. With the administration of P-αB1, 
P-αB2, P-αB3, and P-αB4, the diameter of the villi reach-
es the level of the intact animals.
The same pattern can be observed when estimating the 
size of the maternal and fetal parts of the placenta (Figure 
2A). The most pronounced effect was observed when ad-
ministering the innovative peptides mimicking the α-helix 
B of erythropoietin under laboratory codes P-αB1, P-αB3, 
and P-αB4. The minimal effect was observed when using 
P-αB5 and P-αB6. When administering peptide P-αB3, 
the pronouncement of the effect was intermediate.
The analysis of fetal height indicators in the animals 
with ADMA-like preeclampsia revealed the following 
pattern in the effects of the innovative peptides mimicking 
the α-helix B of erythropoietin. All the studied peptides 
did not significantly affect the height (length) of the fetus 
(Fig. 2B). When administering all the studied peptides, an 
increase in fetus weight was observed in comparison with 
the group of control animals’ fetuses. However, it should 
be noted that a more sensitive indicator (the ratio of height 
and weight) did not reach a statistically significant level 
compared to that in the control group of animals when 
P-αB6 was administered.
Thus, on the basis of the results of the experiment, it is 
possible to identify the following patterns. The base com-
pound with the laboratory code P-αB having the amino 
acid sequence (U/Q)EQLERALNSS at a dose of 50 μg/
kg shows pronounced protective properties in the simu-
lated ADMA-like preeclampsia, but the target level is not 
reached. The addition of the tripeptide motifs RGD, KGD 
leads to an increase in protective effects of the innovative 
peptides mimicking the α-helix B of erythropoietin. How-
ever, it should be noted that the level of some indicators 
reaches the target level. The most pronounced effects are 
shown for the compound P-αB4, obtained by the addition 
the KGD motif to the base peptide. This compound we 
chose for the next series of experiments.
In the treatment of any pathology, a pharmacotherapy 
based on a comprehensive approach occupies a privileged 
position. By affecting various pathogenetic links, more 
opportunities are created for achieving the desired result 
or relieving a severe condition. Based on this, it is self-ev-
ident that the new drugs will be used in combination with 
the drugs already included in the treatment standards or 
recommended for treatment. These circumstances prede-
termined the final series of the experiments for this stage 
of research aimed at studying the effectiveness of an in-
novative peptide that mimics the alpha-helix B of eryth-
ropoietin P-αB4 in combination with a drug included in 
the standards for the treatment of hypertensive conditions 
in pregnant women in the correction of morphofunctional 
disorders in ADMA-like preeclampsia.
The effect of P-αB4 peptide in combination with met-
hyldopa on the development of morphofunctional di-
sorders in ADMA-like preeclampsia
The combined administration of the peptide mimicking 
the α-helix B of erythropoietin P-αB4 and the drug inclu-
ded in the standard therapy of hypertensive conditions in 
pregnant women during the correction of morphofunctio-
nal disorders in experimental preeclampsia led to mutual 
potency of their effects (Table 3). This resulted in a more 
pronounced decrease in blood pressure. The potentiation 
of the effects was especially pronounced after using P-αB4 
at a dose of 10 μg/kg, with blood pressure almost reaching 
the level of that in the group of intact animals (Table 3). In 
both groups administered with P-αB4 at a dose of 50 μg/
kg, arterial pressure was not statistically distinguishable 
from that in the group of intact animals, so a statistically 
reliable pattern of lowering blood pressure is debatable.
In addition, there was an improvement in endothelial 
function, which is evidenced by a decrease in the coeffi-
cient of endothelial dysfunction. In the case of adminis-
tering the combination P-αB4 at a dose of 50 μg/kg with 
methyldopa, the coefficient of endothelial dysfunction 
reached a level not statistically distinguishable from that 
in the group of intact animals (Table 3). In the group of 
animals administered with P-αB4 at a dose of 10 μg/kg 
with methyldopa, the coefficient of endothelial dysfunc-
tion also decreased, but did not reach the level of the in-
tact animals.
In both groups with the combined administration of 
P-αB4 and methyldopa, there was a marked improvement 
in placental microcirculation. However, it should be not-
ed that the target level of the intact animals could not be 
reached (Table 3).
The study of NO-producing function in the animals 
with ADMA-like preeclampsia treated with the combi-
nation of the peptide mimicking the α-helix B of eryth-
ropoietin P-αB4 at the doses of 10 μg/kg and 50 μg/kg 
with methyldopa showed the most pronounced effect at a 
higher dose (Table 3). However, it should be noted that in 
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Figure 2. The effect of innovative peptides mimicking the α -helix B of erythropoietin on the size of the fetal and maternal parts of 
the placenta (A) and the height weight ratio of the fetuses (B) in ADMA-like preeclampsia. Note: * – p < 0.05 in comparison with 
the group of intact animals; y – p < 0.05 in comparison with the L-NAME group.
Table 3. The Effect of Innovative Peptide Mimicking the α-helix B of Erythropoietin P – αB4 on Functional Parameters in AD-
MA-like Preeclampsia (M ± m; n = 10).
Group Indicator




Proteinuria, g/L NOx, µmol/DL Edema of 
the greater 
omentum, %
Intact 128.8±2.61y 80.8±3.27y 1.25±0.04y 541±23.4y 0.29±0.10y 2.22±0.04y 44.74±1.16y
L-NAME 202.8±6.86* 138.4±2.95* 3.11±0.20* 218±6.4* 2.57±0.11* 1.36±0.05* 54.12±1.31*
Methyldopa
(0.086 g/kg)
159.1±3.53*y 111.2±4.05*y 2.31±0.11*y 243±7.2*y 1.71±0.15*y 1.64±0.03*y 49.97±0.90*y
P-αB4 (10 μg/kg) 172.4±2.67*y 123.0±2.29*y 2.22±0.12*y 300±9.1*y 2.14±0.07*y 1.71±0.04*y 49.24±0.87*y
P-αB4 (50 μg/kg) 138.3±5.44y 94.0±6.59y 1.80±0.22*y 337±8.7*y 0.51±0.14y 1.80±0.06*y 46.33±0.53*y
P-αB4 (10 μg/
kg) + Methyldopa 
(0.086 g/kg) 
144.5±3.51*y 98.7±3.27*y 1.8±0.09*y 438±15.1*y 1.12±0.10*y 1.88±0.05*y 47.06±0.91y
P-αB4 (50 μg/
kg) + Methyldopa 
(0.086 g/kg)
129.2±2.33y 85.1±2.55y 1.4±0.09y 489.1±9y 0.39±0.10y 2.13±0.05y 45.51±1.00y
Note: SBP and DBP – systolic and diastolic blood pressure; CED – coefficient of endothelial dysfunction; PU – perfusion units; NOx – NO terminal 
metabolites; * – p < 0.05 in comparison with the intact group; y – p < 0.05 in comparison with the L-NAME group.
the group of animals administered with P-αB4 at a dose 
of 10 μg/kg, there was also a potentiation of the effects.
In both groups administered with P- αB4 at a dose of 
50 μg/kg, the severity of proteinuria was at the level of the 
intact animals. Therefore, the potentiation of the effects 
of the studied pharmacological agents is observed when 
adding methyldopa to P- αB4 at a dose of 10 μg/kg (Table 
3). However, it should be noted that the target level of 
proteinuria in this group of animals was not reached.
In the animals with experimental preeclampsia, the 
administration of the studied pharmacological agents 
showed a decrease in the fluid content in the greater 
omentum tissues. In the group treated with the peptide 
mimicking the α-helix B erythropoietin P-αB4 at a dose 
of 50 μg/kg, the level of edema reached that of the in-
tact animals. When a peptide mimicking the α-helix B of 
erythropoietin P-αB4 at a dose of 10 μg/kg or methyldopa 
at a dose of 0.086 g/kg was administered, a pronounced 
positive effect was also observed, but it did not reach the 
target level (Table 3). When adding methyldopa to the 
studied peptide in the group with P-αB4 at a dose of 50 
μg/kg, the level of fluid content remained at the level of 
that in the intact animals. The addition of methyldopa to 
the studied peptide in the group with P-αB4 at a dose of 
10 μg/kg allowed achieving the level of fluid content in 
the intact animals.
In the histological examination, morphometry showed 
that the most pronounced effect for the correction of the 
cell pool in the maternal and fetal parts of the placenta 
was observed in combination of P-αB4 at a dose of 50 μg/
kg and methyldopa. The same pattern can be observed 
when estimating the size of the maternal and fetal parts 
of the placenta (Fig. 3A). The most pronounced effect 
was observed for the innovative peptide mimicking the 
α-helix B of erythropoietin P-αB4 at a dose of 50 μg/kg 
in combination with methyldopa. The minimal effect was 
observed for methyldopa in the studied dose. In the other 
experimental groups administered with the studied phar-
macological agents in other modes of administration, the 
pronouncement of the effect was at the intermediate level.
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Figure 3. The effect of the innovative peptide mimicking the α-helix B of erythropoietin P- αB4 in combination with methyldopa on 
the size of the maternal and fetal parts of the placenta (A) and the height weight ratio of fetuses (B) in experimental preeclampsia. 
Note: * – р < 0.05 in comparison with the intact group; y – р < 0.05 in comparison with the L-NAME group.
When analyzing fetal growth indicators in the animals 
with ADMA-like preeclampsia, the most pronounced ef-
fect was observed in the group with a combined use of the 
peptide mimicking the α-helix B of erythropoietin P-αB4 
at a dose of 50 μg/kg (Fig. 3B). However, it should be 
noted that the target level, not statistically different from 
that in the group of intact animals, was not achieved.
Thus, the results of the final series of experiments sug-
gest the presence of a potentiating effect of the innovative 
peptide mimicking the α-helix B of erythropoietin P-αB4 
in combination with methyldopa on the correction of 
morphofunctonal disorders in ADMA-like preeclampsia.
Preeclampsia is a complex multi-factorial disease and is 
traditionally characterized by a combined manifestation of 
edema, hypertension, and proteinuria. According to various 
authors, it affects from 2% to 10% of all pregnancies (Mes-
serli et al. 2019; Tomimatsu et al. 2019; un Nisa et al. 2019).
The explanation of pathogenetic events in the modern 
view is provided in more than 30 theories concerning the 
origin and development of preeclampsia. One of the trig-
gers is incorrect placentation as a result of impaired troph-
oblast invasion during pregnancy, which leads to placental 
ischemia (Seamon et al. 2020). Placental ischemia caus-
es the release of a large number of humoral factors that 
provoke endothelial dysfunction of the mother’s systemic 
vessels (Granger et al. 2018). In addition, in the patho-
genesis of preeclampsia, a significant part is played by a 
disruption of platelet function, as evidenced by a decrease 
in the number of platelets, an increase in the average vol-
ume of platelets, and an increase in plasma concentrations 
of beta-thromboglobulin and platelet factor 4 (Jakobsen et 
al. 2019). Progression of thrombocytopenia and increased 
platelet activation are the early laboratory predictors of 
preeclampsia (Jakobsen et al. 2019).
Based on the main features of preeclampsia, one of 
the promising directions for creating new drugs for the 
treatment and prevention of preeclampsia is the use of 
drugs with anti-ischemic and cytoprotective activities. 
Such drugs are erythropoietin medications, which are al-
lowed for use in pregnant women with other indications. 
The previous studies have shown high protective activi-
ty of erythropoietin in various simulated pathologies and 
in many pathological conditions (Robertson et al. 2012; 
Lin et al. 2017; Huang et al. 2018). In the experimental 
studies, recombinant erythropoietin has demonstrated 
pronounced effects on correction of morphofunction-
al disorders in experimental preeclampsia (Gureev et 
al. 2012; Gureev 2016; Lokteva et al. 2020). However, 
the presence of an undesirable erythropoietic effect and 
pro-aggregational properties in ischemic events limits the 
variation of its doses (Kittur et al. 2013; Yanagawa et al. 
2013; Kapitsinou et al. 2015).
Particular interest in erythropoietin is caused by pub-
lished studies, which showed the possibility of separating 
the erythropoietic and pleotropic effects of erythropoie-
tin (Robertson et al. 2012; Collino et al. 2015). The bone 
marrow megakaryocytes have a homodimeric receptor 
(EPOR/EPOR) (Lin et al. 2017; Huang et al. 2018). In 
other tissues, there is a heterodimeric receptor (EPOR-
βCR), so-called the innate repair receptor (IRR) (Culver et 
al. 2017; Lin et al. 2017; Wu et al. 2017; Yan et al. 2018).
A logical continuation of this trend was an experimen-
tal study of recombinant erythropoietin derivatives that do 
not have an erythropoietic activity. Asialo-erythropoietin 
and carbamylated darbepoetin were used as such deriva-
tives. In experimental preeclampsia, both pharmacolog-
ical agents improved the endothelial function, increased 
placental microcirculation, and reduced placental ischem-
ic damage (Weber-Schoendorfer et al. 2015). However, 
it must be acknowledged that these derivatives also have 
a large mass, which is not an optimal property given the 
passage of the molecule through tissue barriers.
A fundamentally new approach is to search for low-mo-
lecular-weight peptide derivatives of EPO that have an-
ti-ischemic and cytoprotective activities. The first such 
derivative is 11-amino acid peptide pHBSP (PubChem 
CID: 91810664), which is an amino acid chain (Pyr/Gl-
n)-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser and has a 
selective affinity for heterodimer complex EPOR/CD131 
(Hache et al. 2016). When developing this peptide, the au-
thors drew on the amino acid sequence of the α-helix B of 
erythropoietin, since this is the only structural part of the 
molecule that does not participate in spatial interaction 
with the EPOR/EPOR homodimeric complex. A number 
of studies have shown that pHBSP has greater antiapoptic 
properties compared to the base molecule, demonstrates 
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an analgesic activity, but does not have a hematopoietic 
effect of EPO (Hache et al. 2016).
A short peptide chain determines not only more fa-
vorable properties in terms of passing through tissue 
barriers, but also creates the possibility of adding short 
peptide motifs with predetermined properties to in or-
der to provide new derivatives with them. Taking into 
account the fact that the malfunction of the hemostasis 
system, in particular, the disruption of the aggregation 
ability of platelets plays a special part in the pathogenesis 
of preeclampsia and its complications, interesting poly-
peptide motifs are represented by RGD (Arg-Gly-Asp), 
KGD (Lys-Gly-Asp), and PGP (Pro-Gly-Pro). which are 
known for their anti-aggregation properties (Pastorova et 
al. 2001; Lyapina et al. 2007; Liapina et al. 2010; Kuo et 
al. 2019). The resulting derivatives were the object of the 
study described in the present paper.
Based on the results of the presented experiment, the fol-
lowing patterns can be identified. The derivatives obtained 
by adding tripeptide motifs to pHBSP peptide retain their 
cytoprotective activity in simulated oxidative stress in HU-
VEC cell culture at the doses of 5 mcg/ml, 30 mcg/ml, and 
50 mcg/ml. The compounds with laboratory codes PaB1 
and PaB3 had the most pronounced cytoprotective activity.
The base compound with the laboratory code P-aB 
having the amino acid sequence (U/Q)EQLERALNSS at 
a dose of 50 μg/kg shows pronounced protective proper-
ties in simulated ADMA-like preeclampsia, but the tar-
get level is not reached. The addition of tripeptide motifs 
RGD, KGD leads to an increase in the protective effects 
of the innovative peptides mimicking the α-helix B of 
erythropoietin. And it should be emphasized that the level 
of some indicators reaches the target level. The most pro-
nounced effects are shown for P-aB4 obtained by adding 
the KGD motif to the base peptide.
The obtained results can be explained by the ability of 
the peptides selectively bind to EPOR-βCR. In this case, 
pleotropic effects specific to recombinant erythropoietin 
are realized: anti-ischemic, anti-apoptotic, and anti-in-
flammatory (Zhang et al. 2017a; Zhang et al. 2017b; Tan 
et al. 2018). This contributes to cytoprotective effects 
in the fetoplacental complex, reducing the formation of 
humoral factors that cause endothelial dysfunction and 
eNOS activation. In addition, the effectiveness of the in-
itial peptide mimicking the α-helix B of erythropoietin 
can be enhanced by addition of the polypeptide motifs 
with antiplatelet properties to it (Kuo et al. 2019). In 
preeclampsia, the interaction of activated platelets with 
the endothelium contributes to the aggravation of its dys-
function, which creates a vicious circle. The endothelium 
with dysfunction of the vascular system loses its anti-
platelet properties, thus creating conditions for more in-
tensive platelet activation. A logical explanation for the 
potentiation of the protective properties of the innova-
tive peptides in the correction of morphofunctional dis-
orders in experimental preeclampsia is the mechanism 
that leads to the interruption of the pathogenetic events 
described above.
The results of the final series of the experiments re-
vealed the presence of the potentiating effect of the inno-
vative peptide mimicking the α-helix B of erythropoietin 
P-αB4 in combination with methyldopa in the correction 
of morphofunctonal disorders in ADMA-like preeclamp-
sia. This effect is explained by the ability to affect dif-
ferent application sites, using multiple pharmacological 
agents. Since a complex therapy plays a leading role in 
the treatment of many pathological conditions, including 
preeclampsia, the presence of a potentiating effect also 
indicates the prospects of the chosen direction in the cre-
ation of drugs aimed at the use of modified short-chain 
peptides mimicking the α-helix B of erythropoietin.
Conclusion
1. The innovative peptides mimicking the spatial 
structure of the α-helix B of erythropoietin obtained 
by addition of tripeptide motifs to the pHBSP pep-
tide retain their cytoprotective activity in simulated 
oxidative stress in HUVEC cell culture at the doses 
of 5 mcg/ml, 30 mcg/ml, and 50 mcg/ml. The com-
pounds with laboratory codes PaB1 and PaB3 had 
the most pronounced cytoprotective activity.
2. The innovative peptides mimicking the spatial struc-
ture of the α-helix B of erythropoietin at a dose of 
50 μg/kg cause a pronounced correction of morpho-
functional disorders in ADMA-like preeclampsia. The 
most pronounced protective properties are shown for 
the derivative under the laboratory code P-aB4. This is 
evidenced by a decrease in systolic and diastolic pres-
sure to the levels statistically indistinguishable from 
those in the group of intact animals, a decrease in the 
coefficient of endothelial dysfunction by 1.73 times, 
1.55-time improvement in microcirculation, a 32.4% 
increase in the concentration of the terminal metabo-
lites of NO in plasma, a decrease in proteinuria and 
edema of the greater omentum tissue to the levels of 
those in the intact animals, the restoration of the diam-
eter of villi to the level of that in the intact animals and 
improving other morphometric and histological indi-
cators of the fetoplacental complex and the fetuses.
3. A synergy of effects is observed for a concomitant 
use of the leader compound, an innovative peptide 
mimicking the spatial structure of the α-helix B of 
erythropoietin under laboratory code P-aB4, with a 
drug included in the standards for the treatment of 
hypertensive conditions in pregnant women – meth-
yldopa. This is evidenced by the positive dynamics 
of morphofunctional indicators with greater pro-
nouncement at a dose of 50 mg/kg: a decrease in 
the coefficient of endothelial dysfunction and an in-
crease in the concentration of the terminal metabo-
lites of NO in plasma to the level of that in the intact 
animals, as well as a statistically significant increase 
in microcirculation in the placenta and correction of 
morphometric parameters of the fetoplacental com-
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plex compared to the monotherapy groups treated 
with the studied pharmacological agents.
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